Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Shares Outstanding (2024 - 2025)

Xilio Therapeutics' Shares Outstanding history spans 2 years, with the latest figure at $51.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 17.91% year-over-year to $51.8 million; the TTM value through Sep 2025 reached $51.8 million, up 17.91%, while the annual FY2024 figure was $45.8 million, N/A changed from the prior year.
  • Shares Outstanding for Q3 2025 was $51.8 million at Xilio Therapeutics, roughly flat from $51.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $51.8 million in Q3 2025 and bottomed at $34.5 million in Q1 2024.